Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service EP ablation cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 83 | 3,424 | 47% |
| 2020 | 81 | 3,283 | 49% |
| 2021 | 95 |
AF, SVT, and VT catheter ablation. Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 22% of the cases CMS names in Pennsylvania; 76 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 138 | 7,854+9.3%/yr | +9.3%/yr | 3.6 | 0% | 15,300 in 2030+12%/yr |
| Massachusetts | 73 | 4,222 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 147 | 7,396−2.8%/yr | −2.8%/yr | 5.61.2× | 2% | 6,810 in 2030−1.4%/yr |
| LAA occlusion & loop recorders |
EP ablation in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
| 2024 |
| 5,803 |
| 58% |
| 2025 est. | ≈ 7,440 | – |
| 2026 est. | ≈ 8,170 | – |
| 3,964 |
| 51% |
| 2022 | 108 | 4,504 | 53% |
| 2023 | 114 | 4,951 | 56% |
| 2024 | 131 | 5,803 | 58% |
| 2025 from claims | – | 7,435 6,823–7,866 | 59% |
| 2026 forecast | – | 8,167 7,186–9,425 | 59% |
| 2027 forecast | – | 8,871 7,584–10,572 | 59% |
| 2028 forecast | – | 9,634 8,039–11,797 | 60% |
| 2029 forecast | – | 10,461 8,544–13,119 | 60% |
| 2030 forecast | – | 11,357 9,098–14,554 | 61% |
In 2025, 15% inpatient hospital, 85% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +12%/yr |
| 4.0 |
| 0% |
| 9,560 in 2030+15%/yr |
| New Jersey | 61 | 3,055+5.7%/yr | +5.7%/yr | 2.5 | 0% | 5,460 in 2030+10%/yr |
| Connecticut | 25 | 921+6%/yr | +6%/yr | 2.3 | 0% | 1,750 in 2030+11%/yr |
| New Hampshire | 11 | 595+16%/yr | +16%/yr | 2.3 | 0% | 1,590 in 2030+18%/yr |
| Maine | 10 | 404+10%/yr | +10%/yr | 2.1 | 0% | 870 in 2030+14%/yr |
| Rhode Island | 8 | 382+4.9%/yr | +4.9%/yr | 3.4 | 0% | 920 in 2030+16%/yr |
| Vermont | 6 | 187+11%/yr | +11%/yr | 1.5 | 0% | 630 in 2030+22%/yr |
| 139 |
| 4,787+8.9%/yr |
| +8.9%/yr |
| 3.00.9× |
| 14% |
| 7,520 in 2030+7.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 42% of company spending on these surgeons in 2025, −14 pts on 2024.
In 2025, 7 companies reported engagement with Pennsylvania’s surgeons worth $1.0M in consulting, speaking, meals and travel tied to these products, about $7,811 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.